Phase I study to characterize pharmacokinetics (PK) of topotecan (T) at 4 mg/m2 administered weekly as a 30-minute IV infusion No significant financial relationships to disclose. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback